Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Yao WangChengxia JiangXiaolin DongMingwei ChenQin GuLihui ZhangYanqin FuTianrong PanYan BiWeihong SongJing XuWeiPing LuXiaodong SunZi YeDanli ZhangLiang PengXiang LinWei DaiQuanren WangWenying YangPublished in: Diabetes, obesity & metabolism (2024)
For patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy, the co-administration of retagliptin and henagliflozin yielded more effective glycaemic control through 24 weeks compared with the individual agents at their corresponding doses.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- open label
- phase iii
- type diabetes
- newly diagnosed
- ejection fraction
- chronic kidney disease
- study protocol
- phase ii
- prognostic factors
- randomized controlled trial
- stem cells
- cross sectional
- mesenchymal stem cells
- patient reported
- smoking cessation